Basic information
- CAS
2413-38-9- Standard SMILES
Cl.Cl.OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1- InChIKey
IOVDQEIIMOZNNA-MHKBYHAFSA-N- Molecular formula
- C23H27Cl2F3N2OS
- Average molar mass
- 507.4 g/mol
- Monoisotopic mass
- 506.1173245
Overview
Cis-flupenthixol dihydrochloride is the dihydrochloride salt of cis-flupenthixol. It has a role as a geroprotector. It contains a cis-flupenthixol(2+).
Names & identifiers
- Preferred name
- Flupentixol Dihydrochloride
- IUPAC
- 2-[4-[(3Z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol;dihydrochloride
- English name
- Fupentixol dihydrochloride
- Molecular formula
- C23H25F3N2OS.2ClH
- Molecular weight
- 507.44
Names & synonyms
2413-38-9FLUPENTIXOL DIHYDROCHLORIDEEmergilFlupentixol HClFlupentixol hydrochlorideMetaminHAT84MLQ6Z96L0Z069N1FluanxolSiplarol1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, dihydrochloride, (Z)-Depixol
Show more names
flupentixolhydrochloride(E/Z)-Flupentixol Dihydrochloridefx703Fupentixol HClFlupentixol 2HClFlupenthixol dihydroFluanxol dihydrochlorideHydrochloric Flupentixol
DTXSID9058737RefChem:599453DTXCID2032429219-321-451529-01-2Flupenthixol dihydrochloridecis-(Z)-Flupenthixol dihydrochlorideFupentixol dihydrochloride
Database identifiers
- CAS
2413-38-9、51529-01-2- PubChem CID
- 5282483
- DTXSID
Properties
Computed structural properties
- Topological polar surface area
- 52 Ų
- Hydrogen bond donors
- 3
- Hydrogen bond acceptors
- 7
- Rotatable bonds
- 5
- Heavy atoms
- 32
- Formal charge
- 0
- Complexity
- 591
Experimental & physicochemical properties
Human DrugsBreast Feeding; Lactation; Milk, Human; Antipsychotic Agents; Dopamine Antagonists
Physicochemical properties
- Melting point
- 237 · 237-239 °C(Solv: ethanol (64-17-5); methanol (67-56-1))
- storage temp.
- 2 · Sealed in dry,2-8°C
- solubility
- 2 O: · H2O: soluble
- form
- solid
- color
- white or off-white
- Water Solubility
- soluble
- Major Application
- pharmaceuticalpharmaceutical small molecule
- InChI
- InChI=1S/C23H25F3N2OS.ClH/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29;/h1-2,4-8,16,29H,3,9-15H2;1H
- InChIKey
- ZQAWQVWCKYGMNE-UHFFFAOYSA-N
- SMILES
- Cl.C(=C1C2=CC=CC=C2SC2=CC=C(C(F)(F)F)C=C12)CCN1CCN(CCO)CC1
- CAS DataBase Reference
- 2413 · 2413-38-9
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P321, P330, P362+P364, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
This chemical does not meet GHS hazard criteria for 3.2% (1 of 31) of reports.
Warning
Hazard information
Hazard Classes and Categories
Acute Tox. 4 (96.8%)
Acute Tox. 4 (100%)
Toxicology
Exposure RoutesFairly slow and incomplete after oral administration
Toxicity Summary
Flupenthixol is a thioxanthene antipsychotic. The mechanism of action of Flupenthixol is not completely understood. Flupenthixol is a powerful antagonist of both D1 and D2 dopamine receptors, and an alpha-adrenergic receptor antagonist. It's antipsychotic activity is thought to be related to blocks postsynaptic dopamine receptors in the CNS.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD50: 300 mk/kg (Oral,Mouse) (A308)
LD50: 791 mg/kg (Oral, Rat) (A308)
LD50: 87 mk/kg (Intravenous, Mouse) (A308)
LD50: 37 mg/kg (Intravenous, Rat) (A308)
Chemistry & industry
Pharmacology
Metabolism/MetabolitesMainly hepatic
Half Life: 19 to 39 hours
MeSH Pharmacological Classification
A traditional grouping of drugs said to have a soothing or calming effect on mood, thought, or behavior. Included here are the ANTI-ANXIETY AGENTS (minor tranquilizers), ANTIMANIC AGENTS, and the ANTIPSYCHOTIC AGENTS (major tranquilizers). These drugs act by different mechanisms and are used for different therapeutic purposes.
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
Uses & manufacturing
UsesFor use in the treatment of schizophrenia and depression
Applications
UsesNeuroleptic agent related structurally to thiothixene. Antipsychotic; neuroleptic agent; dopamine receptor antagonist.
Upstream & downstream products
Upstream raw materials
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…